Top

Clinical and Translational Oncology

Published in:

01-04-2017 | Research Article

Intratumoral heterogeneity of CD44v6 in rectal cancer

Authors: H.-G. Liu, L. Lv, H. Shen

Published in: Clinical and Translational Oncology | Issue 4/2017

Abstract

Purpose

CD44v6 plays a controversial role in tumor progression and patient outcome in colorectal cancer by plenty of conflicting reports. The purpose of this study was to profile the intratumoral heterogeneity of CD44v6 in rectal cancer and investigate its role in lymph node metastasis.

Methods

Sixty patients were included in this study. Immunohistochemistry for CD44v6 was performed in normal mucosa, primary tumor, and lymph node metastasis with whole tissue sections. The staining intensity in tumor center and invasive front was separately measured. Sampling bias was evaluated by quantitative real-time PCR with 15 pairs of frozen tissues from different sites of the primary tumor.

Results

CD44v6 expression increased from normal mucosa to primary tumor to lymph node metastasis. Multiple intratumoral staining patterns was observed in primary tumor, and CD44v6 expression in invasive front was significantly higher than that in tumor center. In addition, mRNA expression levels differed across different geographical regions of the tumor. No association between CD44v6 expression and lymph node metastasis was revealed.

Conclusions

Substantial intratumoral heterogeneity of CD44v6 exists in rectal cancer that impacts the outcome of individual studies. CD44v6 expression should be assessed in a more precise way with a specified staining pattern and in a designated location.

Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11(4):254–67. doi:10.1038/nrc3023.CrossRefPubMed

Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, et al. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate. 2014;74(6):602–17. doi:10.1002/pros.22775.CrossRefPubMed

Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, et al. CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep. 2013;29(4):1570–8. doi:10.3892/or.2013.2273.PubMed

Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14(3):342–56. doi:10.1016/j.stem.2014.01.009.CrossRefPubMed

Bendardaf R, Elzagheid A, Lamlum H, Ristamaki R, Collan Y, Pyrhonen S. E-cadherin, CD44 s and CD44v6 correlate with tumour differentiation in colorectal cancer. Oncol Rep. 2005;13(5):831–5.PubMed

Zlobec I, Gunthert U, Tornillo L, Iezzi G, Baumhoer D, Terracciano L, et al. Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology. 2009;55(5):564–75. doi:10.1111/j.1365-2559.2009.03421.x.CrossRefPubMed

Wang L, Liu Q, Lin D, Lai M. CD44v6 down-regulation is an independent prognostic factor for poor outcome of colorectal carcinoma. Int J Clin Exp Pathol. 2015;8(11):14283–93.PubMedPubMedCentral

Afify A, Durbin-Johnson B, Virdi A, Jess H. The expression of CD44v6 in colon: from normal to malignant. Ann Diagn Pathol. 2016;20:19–23. doi:10.1016/j.anndiagpath.2015.10.010.CrossRefPubMed

Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338–45. doi:10.1038/nature12625.CrossRefPubMed

10.

Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature. 2013;501(7467):355–64. doi:10.1038/nature12627.CrossRefPubMedPubMedCentral

11.

Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108(3):479–85. doi:10.1038/bjc.2012.581.CrossRefPubMedPubMedCentral

12.

Lv L, Liu HG, Dong SY, Yang F, Wang QX, Guo GL, et al. Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells. Tumour Biol. 2016;. doi:10.1007/s13277-015-4755-6.

13.

de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest. 2005;85(1):154–9. doi:10.1038/labinvest.3700208.CrossRefPubMed

14.

Coppola D, Hyacinthe M, Fu L, Cantor AB, Karl R, Marcet J, et al. CD44V6 expression in human colorectal carcinoma. Hum Pathol. 1998;29(6):627–35.CrossRefPubMed

15.

Finke LH, Terpe HJ, Zorb C, Haensch W, Schlag PM. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet. 1995;345(8949):583.CrossRefPubMed

16.

Peng J, Lu JJ, Zhu J, Xu Y, Lu H, Lian P, et al. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer. Cancer J. 2008;14(1):54–61. doi:10.1097/PPO.0b013e3181629a67.CrossRefPubMed

17.

Weg-Remers S, Anders M, von Lampe B, Riecken EO, Schuder G, Feifel G, et al. Decreased expression of CD44 splicing variants in advanced colorectal carcinomas. Eur J Cancer. 1998;34(10):1607–11.CrossRefPubMed

18.

Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4(1):33–45. doi:10.1038/nrm1004.CrossRefPubMed

19.

Avoranta ST, Korkeila EA, Syrjanen KJ, Pyrhonen SO, Sundstrom JT. Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence. World J Gastroenterol. 2012;18(33):4549–56. doi:10.3748/wjg.v18.i33.4549.CrossRefPubMedPubMedCentral

20.

Huang J, Pan C, Hu H, Zheng S, Ding L. Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PLoS One. 2012;7(10):e47901. doi:10.1371/journal.pone.0047901.CrossRefPubMedPubMedCentral

21.

Damm S, Koefinger P, Stefan M, Wels C, Mehes G, Richtig E, et al. HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta. J Invest Dermatol. 2010;130(7):1893–903. doi:10.1038/jid.2010.45.CrossRefPubMedPubMedCentral

22.

Klingbeil P, Marhaba R, Jung T, Kirmse R, Ludwig T, Zoller M. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res. 2009;7(2):168–79. doi:10.1158/1541-7786.MCR-08-0207.CrossRefPubMed

Title: Intratumoral heterogeneity of CD44v6 in rectal cancer
Authors: H.-G. Liu
L. Lv
H. Shen
Publication date: 01-04-2017
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 4/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-016-1542-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2017

Comparison of clinicopathological features and prognosis of gastric cancer located in the lesser and greater curve

Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists

Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis

Predictive value of hypoxia in advanced head and neck cancer after treatment with hyperfractionated radio-chemotherapy and hypoxia modification

Accelerated hypofractionated radiation therapy (AHRT) for non-small-cell lung cancer: can we leave standard fractionation?

Telomeres and telomerase in the clinical management of colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer